Nyxoah S.A.
NYXH
$-0.15
Change (1 day)
$20.00
Year High
$4.00
Year Low
Categories
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Earnings for Nyxoah S.A. (NYXH)
Earnings in 2023 (TTM): $-44,657,000
According to Nyxoah S.A.'s latest financial reports the company's current earnings (TTM) are $-44,657,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Nyxoah S.A.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-44,657,000 | $-43,212,000 |
| 2022 | $-30,056,000 | $-31,225,000 |
| 2021 | $-24,639,000 | $-27,619,000 |
| 2020 | $-12,152,000 | $-12,245,000 |
| 2019 | $-7,185,000 | $-7,255,000 |
| 2018 | $-9,038,000 | $-9,079,000 |
| 2017 | $-10,334,000 | $-10,371,000 |